Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe

Four different cost effectiveness analyses have been summarised.

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe

Fludarabine as second line therapy for B-cell chronic lymphocytic leukaemia: Cost-effectiveness annexe
25 September 2001
(31.75 Kb 9 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 30 March 2010